Abstract 1958P
Background
ADT is an established treatment for PCa, influencing different aspects of tumor biology. The study aimed to assess expression of EMT (E- and N-cadherins (cad)) and CSC (CD44, CD133) markers as well as androgen (AR) and estrogen (ERα, ERβ) receptors and transforming growth factor beta type II receptor (TβRII) (an EMT regulator) in localized PCa samples after ADT.
Methods
56 radical prostatectomy cases were analyzed. 15 of them had 3-6 months of ADT before surgery. Double immunofluorescent staining was used. For E-cad and CD44 staining intensity was assessed, for CD133 – presence of staining, for N-cad– weighed staining index (WSI) and for AR, ERα, ERβ and TβRII – total staining scores (TSS) per case.
Results
In the studied cohort expression of EMT and CSC markers didn’t differ significantly in cases after ADT and without it (pχ2=0.71 for CD133, pMann-Whitney>0,05 for all other markers), that may assume that at least at the early stage of PCa development short-term ADT doesn’t influence these phenotypes. AR and ER expression both in stroma and epithelium didn’t differ significantly, except for ERβ in cancer cells nuclei, that appeared to be higher after ADT (TSS 6.00 vs. 3.25, pMann-Whitney=0.042). Expression of TβRII appeared to be significantly higher for nuclear and lower for membranous staining in ADT cases (Mann-Whitney test, TSS 2.33 vs. 1.20, p=0.002 and 0 vs. 0.58, p<0.001, respectively). Only in ADT cases CD44 was significantly higher in CD133+ tumors, and N-cad WSI correlated with CD44 expression, while ERα in both stroma and cancer cells correlated with epithelial AR (r=0.55 and r=0.54, pSpearman<0,05), though these associations were not seen in cases without ADT. Also moderate direct correlation was seen between nuclear TβRII and E-cad (r=0.52, pSpearman<0,05). Markers expression in pre-ADT biopsies and their dynamic changes on ADT could not be assessed.
Conclusions
ADT influences TβRII and ERβ expression in cancer cells and also modulates EMT and CSC markers and regulators correlations, that may assume that though ADT alone is not sufficient to induce EMT or CSC phenotypes, it may modulate intra-tissue interactions of signaling cascades and alter cell responses to regulating signals.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
M. Puchinskaya.
Funding
Belarusian Republican Foundation for Fundamental Research, grants No. M14M-143, M19M-123.
Disclosure
M. Puchinskaya: Financial Interests, Personal, Invited Speaker: Roche.
Resources from the same session
252P - Evolution of breast cancer biological subtypes between pre-treatment biopsy and residual disease after neoadjuvant therapy
Presenter: Katarzyna Pogoda
Session: Poster session 13
253P - Single-cell RNA sequencing reveals tumor heterogeneity and potential mechanisms of response/resistance in breast cancer treated with neoadjuvant therapy
Presenter: Marcela Carausu
Session: Poster session 13
254P - IHC and GEX biomarkers and their prognostic and treatment predictive role in the neoadjuvant treatment of breast cancer
Presenter: Hani Saghir
Session: Poster session 13
255P - Predicting early recurrence in breast cancer patients undergoing neo-adjuvant chemotherapy through MRI-radiomics analysis
Presenter: Anna D'Angelo
Session: Poster session 13
256P - Protein signature of tertiary lymphoid structure predicts efficacy of neoadjuvant chemotherapy in triple-negative breast cancer
Presenter: Shuling Zhou
Session: Poster session 13
257P - Spatial predictors of pathologic complete response to neoadjuvant chemotherapy using imaging mass cytometry in the IMMUcan TNBC cohort
Presenter: Andrea Joaquin Garcia
Session: Poster session 13
258P - Correlation between pathological complete response (pCR) following neoadjuvant docetaxel, carboplatin and trastuzumab (TCH) with or without pertuzumab (TCHP) and PAM50 subtypes in HER2(+) early breast cancer (eBC)
Presenter: Coralia Bueno Muiño
Session: Poster session 13
1954P - 5-methylthioadenosine phosphorylase (MTAP) loss in clinically advanced uveal melanoma (CAUM): A comprehensive genomic profiling (CGP) study
Presenter: Nimisha Srivastava
Session: Poster session 13
1955P - Glycan-programmed T cell immunity: Effective adoptive T cell transfer in a CRC preclinical model
Presenter: Yong Miao
Session: Poster session 13